Login / Signup

Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019-2022.

Andrew ChouDavid J RamseyEva M AmentaBarbara W Trautner
Published in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2023)
In this nationwide VHA cohort clinical and microbiologic failure occurred in >30% of patients treated with cefiderocol, and >40% of these died within 90 days. Cefiderocol is not widely used, and many of the patients who received it had substantial comorbidities.
Keyphrases